Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Enhertu Market Expansion From $ Billion In 2026 To $ Billion In 2030
The expansion observed during the historical timeframe has been driven by a higher incidence of HER2-positive cancers, the shortcomings associated with traditional chemotherapy, the initial achievements of targeted treatment approaches, breakthroughs in molecular diagnostic technologies, and a growing number of oncology drug approvals.
The anticipated expansion during the forecast period is driven by broader applications for antibody-drug conjugates, greater uptake of HER2 testing, heightened demand for precision oncology approaches, robust investment in cancer research, and encouraging results from clinical trials. Key developments shaping this period encompass the rise of antibody-drug conjugate-based cancer treatments, the advancement of HER2-specific targeted therapies, the broadening scope of precision oncology, increasing reliance on biomarker-guided cancer management, and a transition toward later-line targeted therapeutic strategies.
Download A Free Sample Report For Comprehensive Market Insights:
Enhertu Market Development Factors: Which Trends Are Supporting Demand?
The growing occurrence of breast cancer is anticipated to boost the enhertu market in the coming years. Breast cancer originates in breast tissue, typically within the milk ducts or lobules, and has the potential to metastasize to other body parts. This rise in cases stems from various causes, including an older population, hereditary factors, lifestyle choices like unhealthy eating and insufficient exercise, environmental influences, and enhanced diagnostic and screening techniques. Enhertu offers a focused treatment for breast cancer patients by combining chemotherapy with HER2-targeted therapy, significantly enhancing results for those suffering from advanced or metastatic HER2-positive breast cancer. For example, per September 2023 data from Breast Cancer Now, a UK charity, around 600,000 individuals in the UK are currently living post-breast cancer diagnosis, with projections indicating this will double to 1.2 million by 2030. Consequently, the increasing breast cancer prevalence is fueling expansion of the enhertu market.
Enhertu Market Segment Landscape: Which Areas Lead Market Development?
The enhertu market covered in this report is segmented –
1) By Indication: HER2-Positive Metastatic Breast Cancer, HER2-Low Metastatic Breast Cancer, HER2-Mutant Non-Small Cell Lung Cancer (NSCLC), HER2-Positive Metastatic Gastric Cancer
2) By Treatment Line: First-Line Therapy, Second-Line Therapy, Third-Line Therapy
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies
Enhertu Market Transformation Trends: Which Innovations Are Driving Change?
A central development in the Enhertu market focuses on expanding its approved uses through clinical trials aimed at treating various cancers, such as non-small cell lung cancer (NSCLC) and colorectal cancer, extending well beyond its established role in HER2-positive breast cancer. These studies support Enhertu’s evolution as a targeted therapy, demonstrating statistically robust and clinically relevant improvements in progression-free survival for patients with HR-positive, HER2-low metastatic breast cancer in the DESTINY-Breast06 Phase 3 trial, following at least one prior line of endocrine therapy. For example, in April 2024, Daiichi Sankyo, a pharmaceutical firm based in Japan, along with AstraZeneca plc from the UK, revealed findings from the DESTINY-Breast06 Phase 3 trial for ENHERTU (trastuzumab deruxtecan). The results confirmed that ENHERTU leads to a substantial enhancement in progression-free survival (PFS) for individuals with hormone receptor (HR)-positive, HER2-low metastatic breast cancer who had undergone at least one prior endocrine therapy. This research is particularly noteworthy because it marks the first instance where a HER2-directed treatment has exhibited a clinically meaningful advantage for this distinct patient group.
Enhertu Market Industry Leaders And Market Competition
Major companies operating in the enhertu market are AstraZeneca Plc, Daiichi Sankyo Co. Ltd.
Access The Complete Enhertu Market Report:
Enhertu Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the enhertu market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enhertu market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model